Friday, February 29, 2008
Firefighter Asbestos Exposure at Department Store Fire
LegalView Informs Readers of Potential Firefighter Asbestos Exposure at a Recent Department Store Fire
LegalView continues to inform readers of the most recent mesothelioma and asbestos news updates on its mesothelioma blog. A recent department store fire has nearly 60 firefighters worried about potential exposure to asbestos
Denver, CO - January 6, 2008 -- LegalView.com, the number one resource for everything legal on the Web, reported on mesothelioma blog that nearly 60 firefighters in a Connecticut town may have been exposed to asbestos after a recent department store fire.
Asbestos is a deadly substance that was used in the construction of homes, schools, government buildings and even in department stores or other commercial constructions. When individuals are exposed to asbestos fibers and asbestos dust they become at risk for mesothelioma cancer. Mesothelioma is a deadly form of cancer that takes decades to reveal itself, by which time, it is often too late to offer treatment for the cancer. Many individuals who have worked in the construction, mining or shipyard industry have been associated with asbestos exposure. If you feel you or your loved one may be in danger of asbestos exposure it is important to seek help immediately. The sooner mesothelioma cancer is found the better the chance is of treating it. After consulting with a mesothelioma doctor, use LegalView's resources to reach a mesothelioma lawyer who may also be able to provide insight into the case.
The department store fire occurred in New Haven, Connecticut. Sixty firefighters had reportedly fought the fire for hours on end with air packs that lasted only 30 minutes. The blog reports that debris from the fire was sent to the Department of Public Health and several samples were found to have tested positive for asbestos. For individuals who feel they have been previously exposed to asbestos, it is important to contact an experienced mesothelioma attorney to receive a consultation.
LegalView offers other legal resources including finding information on traumatic brain injury accidents or an auto accident injury. Millions of Americans are affected by these tragic accidents each and every day and LegalView stands by those suffering from tragedy. LegalView also offers information on how to locate an experience all-terrain vehicle law firm who can provide assistance during a rollover accident.
About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.
Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website: http://www.LegalView.com
Thursday, February 28, 2008
Cancer Drug Synergy Found With Biothera And Avastin
Biothera Drug Synergistic with Avastin® Against Cancer, Study Finds
EAGAN, Minn.- February 28, 2008 -Biothera's Imprime PGGT increased the effectiveness of Avastin® (bevacizumab), a monoclonal antibody approved for the treatment of metastatic colorectal, breast and non-small cell lung cancer, according to a new preclinical study published in the current issue of Clinical Cancer Research.
Researchers in the Tumor Immunobiology Program of the James Graham Brown Cancer Center, University of Louisville, Kentucky, studied the synergistic effects of Imprime PGG in combination with Avastin in a xenograft mouse model where human ovarian cancer cells were implanted into the mice. In the treatment group receiving both Imprime PGG and Avastin, 86% of the mice survived 100 days compared with only 43% in the group receiving Avastin alone.
"Our study is the first to demonstrate that Avastin, an anti-angiogenic agent, co-administered with Imprime PGG, an agent that enhances innate immune effector cell function, results in synergistic anti-tumor effects," said Carolina Salvador, M.D., a clinical instructor at the James Graham Brown Cancer Center. "This type of combination strategy has significant clinical implications and deserves further investigation."
"These results are consistent with our previous research with Imprime PGG and various monoclonal antibodies in numerous cancer indications," said Daniel K. Conners, president of Biothera's Pharmaceutical Group. "We are now working to demonstrate the safety and efficacy of these novel cancer therapies in the clinic."
Biothera is currently conducting a clinical trial with metastatic colorectal cancer patients receiving a combination therapy of Imprime PGG, Erbitux® (cetuximab), a monoclonal antibody from ImClone Systems, and Irinotecan, a chemotherapy drug from Pfizer. The results of the trial are expected later in 2008. The company also plans to initiate a clinical study in lung cancer patients this year using a combination of Imprime PGG, Avastin and two chemotherapy drugs.
The title of the new Clinical Cancer Research paper is "Yeast-Derived ?-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models." The authors are Carolina Salvador, Bing Li, Richard Hansen, Daniel E. Cramer, Maiying Kong and Jun Yan.
About Imprime PGGT
Imprime PGG is a biological response modifier that enhances specific innate immune cell responses. Biothera has completed two Phase I clinical trials under its cancer Investigational New Drug (IND) application for the use of Imprime PGG in combination with anti-cancer monoclonal antibodies. Under a separate IND, the company also has completed a Phase I/II trial with Imprime PGG in combination with a hematopoietic growth factor.
About Avastin®
Avastin was the first anti-angiogenesis therapy approved by the FDA and with last week's approval, is now approved for the treatment of the three leading causes of cancer death in the U.S.: metastatic colorectal cancer, advanced non-squamous, non-small cell lung cancer and metastatic HER2-negative breast cancer. Avastin is a product of Genentech.
About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the innate immune system to fight cancer. Website: www.biotherapharma.com.
Contacts
Biothera, the Immune Health Company
David Walsh, 651-256-4606
VP, Communications
dwalsh@biotherapharma.com
On the list of sites with mesothelioma Minnesota is gaining attention as a location with an increased number of cases diagnosed.
Saturday, February 23, 2008
Clinical Results for Treatment of Anterior Knee Arthritis
In a recent issue of The Journal of Bone & Joint Surgery (JBJS), unparalleled surgical outcomes were reported when using Kinamed's FDA-cleared KineMatch® Patello-Femoral Replacement device which replaces just one part of the knee unlike "total knee replacements" that replace all three compartments of the knee.
Camarillo, CA (PRWEB) December 4, 2007 -- In a recent issue of The Journal of Bone & Joint Surgery (JBJS), unparalleled surgical outcomes were reported when using Kinamed's FDA-cleared KineMatch® Patello-Femoral Replacement device which replaces just one part of the knee unlike "total knee replacements" that replace all three compartments of the knee. Twenty-five (25) consecutive knees were treated with the KineMatch device. At an average follow-up period of 73 months (6+ Years following surgery) all 25 implants were in place and functioning well. There were 18 "Excellent" and 7 "Good" results using the Knee Society scoring method. No patient had required additional surgery or had component loosening.
According to the study's lead author and primary surgeon (Domenick J. Sisto, MD, Los Angeles Orthopaedic Institute, Sherman Oaks, CA), "the KineMatch device has offered a remarkable benefit and return to function for our patients with intractable patello-femoral disease who were otherwise facing the prospect of total knee replacement or patella removal." Dr. Sisto continued, "the KineMatch device is a conservative approach that is appropriate on a unique subset of patients who would otherwise be candidates for more extensive total knee replacement. Another benefit to the KineMatch device is our ability to convert it to a total knee replacement should that become necessary in the future."
Women comprise approximately 75% of patello-femoral arthroplasty patients, due to patello-femoral malalignment and dysplasia which is much more common in women than in men. The problem can also be the result of sports or work-related wear and tear. Pain associated with patello-femoral arthritis is directly under the knee cap and is most severe when using stairs, prolonged walking, walking up hills, squatting and kneeling. The pain is less severe when walking on level surfaces. When sitting, patients with patello-femoral arthritis are more comfortable with their knee straight rather than bent. The typical patient is relatively young when compared to the total knee replacement candidate in this study the average patient was 45 years old and had one or more prior surgical procedures that attempted to treat their knee pain.
The KineMatch Patello-Femoral Replacement device begins with a computed tomography (CT) exam of the patient's knee. The CT data is used to manufacture the KineMatch device, which is custom made for each patient. This is believed to be key to obtaining good clinical results while also offering a very conservative "bone sparing" approach for the younger patient. The surgical procedure itself is also shortened because little bone sculpting is required to implant the device and the recovery time and post-operative rehabilitation time is reduced as compared to what is required after total knee replacement. The cost of the KineMatch device is less than the cost of a typical "high-performance" total knee replacement device and the operative time and recovery period are also less than what one would experience with total knee replacement.
About Kinamed
Established in 1987, Kinamed is a privately held medical device company based in Camarillo, California. Kinamed designs and manufactures implants and instruments for orthopedics and neurosurgery.
For further information, visit www.kinamed.com or contact Vineet Sarin, Ph.D at 805-384-2748 or email contact @ kinamed.com
Press Contact: Vineet Sarin, Ph.D
Company Name: Kinamed, Inc.
Phone: 805-384-2748
Website: www.kinamed.com
Sunday, February 17, 2008
Mesothelioma Symptoms And Steps To Making A Diagnosis
